05/10/2005
Media Relations Contact:
Trista Morrison or Jennifer MacArthur
Atkins + Associates for Kereos
858-527-3490 or 858-527-3497
tmorrison@irpr.com or jmacarthur@irpr.com
St. Louis, MO – May 10, 2005 – Kereos, Inc. h as announced that it will be presenting at 11:55 am on May 19 th at Windhover Information's “The Start-Up Forum 2005”, taking place May 18-20, 2005 at the Cambridge Marriott in Boston , MA . An emerging drug development company, Kereos is developing targeted imaging agents and targeted therapeutics for cancer. Presenting at the conference will be Robert A. Beardsley, Ph.D., President and CEO.
“This conference has consistently highlighted the future stars of our industry, and attracted the leading venture capitalists interested in investing in them,” said Dr. Beardsley. “As such it is an ideal venue for us to present our candidates offering the hope for more effective treatment of cancer and our vision of combining targeted imaging and therapy.”
The Windhover Start-Up Forum is an annual event that brings biotech companies together with investors to encourage funding. Kereos is one in only fifty companies that has been selected to present at this high profile event attended by investors from all over the world. The various presenting companies are a mix of leading emerging companies in biotechnology, pharmaceuticals, medical devices, and diagnostics.
About Kereos:
Kereos develops products designed to provide more effective detection and treatment of cancer, the first two of which are expected to enter clinical trials for solid tumors in 2006. The company's proprietary technology pairs diagnosis and therapy by targeting imaging agents or therapeutics specifically to the disease site. The company's targeted imaging agents allow more accurate and sensitive imaging, and its targeted chemotherapeutics deliver potent and precise therapy. In addition to advancing its internal pipeline, Kereos is working with leading pharmaceutical and imaging companies, including Bristol-Myers Squibb Medical Imaging on the development and commercialization of cardiovascular disease magnetic resonance imaging (MRI) agents and Philips Medical Systems on the development of molecular imaging systems. Kereos is headquartered in St. Louis at the Center for Emerging Technologies. For more information, visit Kereos' website at www.kereos.com.
Back to Press Releases
|
